45 patients were lost mainly due to a safety analysis during the core study including a recruitment stop for the extension study imposed by the local institutional review board (IRB), because a study of Birnbaum et al. suggested a negative effect of statins in combination with IFNB in MS [11]. Here, IFNB1 is linked to myeloid sarcoma.